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Background: Greater anticholinergic burden (ACB) increases the risk of mortality in older
individuals, yet the strength of this association varies between studies. One possible
explanation for this variance is the use of different approaches to quantify ACB. This
systematic review (PROSPERO number CRD42019115918) assessed the prognostic
utility of ACB-specific measures on mortality in older individuals.
Methods: Multiple cross-disciplinary databases were searched from 2006–2018.
Observational studies assessing the association between ACB and mortality utilizing ≥1
ACB measure, involving persons aged ≥65 years were included. Screening and data
extraction were performed by two independent reviewers, with disagreements resolved
by a third independent reviewer. Risk of bias and quality of evidence were assessed using
Quality in Prognosis Studies (QUIPS) and Grading of Recommendations, Assessment,
Development, and Evaluations (GRADE) criteria. Meta-analysis was conducted where
appropriate.
Results: Of 19,224 titles, 20 articles describing 18 cohort studies involving 498,056 older
individuals were eligible. Eight anticholinergic-specific measures were identified; the
Anticholinergic Cognitive Burden Scale (ACBS, n=9) and Anticholinergic Risk scale
(ARS, n=8) were most frequently reported. The evidence base was of poor quality, with
moderate to high risk of bias. Meta-analysis showed increased mortality risk.
Conclusions: There was a modest association between some ACB measures and
mortality, with most evidence derived from the ACBS. Studies comparing different
measures within the same population were lacking. Analysis was limited by poor
generalizability between studies, specifically regarding heterogeneity in methodology
and reporting, as well as high risk of bias for most studies in the evidence base.
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The cumulative use of anticholinergics, termed anticholinergic
burden (ACB), has been highlighted as one problematic area of
polypharmacy in older populations (Hilmer et al., 2007;
Salahudeen et al., 2015). It is estimated that 20–50% of older
persons have been prescribed at least one medication with
anticholinergic activity (Campbell et al., 2009), with increases
in prescribing rates and ACB as individuals age (Lu et al., 2015).
While anticholinergics are useful in conditions such as
depression, incontinence, Parkinson ’s disease , and
gastrointestinal disorders, their broad range of action on the
central and peripheral nervous systems can result in significant
side-effects. Central side-effects include sedation, confusion and
delirium (Rudolph et al., 2008; Fox et al., 2014). Peripheral side-
effects include dry mouth and eyes, tachycardia, and constipation
(Rudolph et al., 2008; Fox et al., 2014). Additionally, concerns
have been raised as to the potential of anticholinergics to
exacerbate physical and mental decline, especially regarding
dementia development (Fox et al., 2014; Myint et al., 2014;
Salahudeen et al., 2015). Consequently, various anticholinergics
have been listed as potentially inappropriate medications for use
in older individuals, as indicated by the Beers Criteria® (The
American Geriatrics Society Beers Criteria® Update Expert Panel
et al., 2019) and STOPP criteria (O’Mahony et al., 2010).
One risk suggested to be associated with greater ACB
amongst older individuals is mortality, although the
significance and strength of this association varies between
studies (Fox et al., 2014). One explanation may lie in how ACB
was quantified. To date, multiple measures exist to assess ACB
but differences are apparent between measures in terms of which
medications are included and the level of anticholinergic potency
attributed to individual medications (Bostock et al., 2013;
Salahudeen et al., 2015). For example, clomipramine is assessed
as having “high” potency according to Boustani et al. (2008) and
Carnahan et al. (2006), yet this drug is not included in the
analysis by Rudolph et al. (2008). Drug availability and
formularies between countries can also impact the ability of
measures, typically developed with the drug formularies of one
country, to be applied internationally (Salahudeen et al., 2015).
Currently, there is no evidence to support the decision to use or
not use one ACB measure above another. Improving this
understanding will allow informed ACB measure choices to be
made and enhance the quality of future research. Therefore, this
systematic review aims to describe the association of individual
ACB measures with mortality in older adults.METHODS
This systematic review, followed Preferred Reporting Items
for Systematic Reviews and Meta-Analyses (PRISMA)
guidance (www.prisma-statement.org; see Supplementary
Table 2 for PRISMA checklist) and was registered with
PROSPERO (www.crd.york.ac.uk/prospero), registration
number CRD42019115918).Frontiers in Pharmacology | www.frontiersin.org 2Literature Search Strategy
MEDLINE (Ovid), EMBASE (Ovid), PsycINFO (Ovid), and
CINAHL (EBSCO) were searched using a comprehensive
search strategy, adapted to suit each specific database. Study
searches were undertaken on 16th November 2018. The
validated search filter utilized to identify prognostic studies was
in line with the recommendations of Geersing et al. (2012). Both
MeSH and text/key words were included. Studies published
between 1st January 2006 and 16th November 2018 were
included. The initial timepoint of 2006 was used as cumulative
ACB was first described during this period. Reference lists and
citation checks of identified eligible studies were reviewed for
further eligible studies. The search strategy is reported in
Supplementary Table 1.
Study Inclusion Criteria
Studies were deemed eligible if they were in accordance with the
following criteria:
• Prospective and retrospective observational studies, for
example longitudinal cohorts and case-control studies from
any setting (e.g., community/primary care/general practice,
secondary care/hospital/acute care, nursing homes/homes).
• Mean study participant age was ≥65 years.
• Human studies investigating the total exposure of
anticholinergic burden by use of ACB-specific measure. The
comparator required was non-users of anticholinergic
medications and outcome of interest was mortality.Study Exclusion Criteria
Studies were excluded if:
• They were systematic reviews, randomized control trials,
cross-sectional studies, opinion/editorial articles, qualitative
studies, or animal studies.
• Study mean age was <65 years.
• Non-anticholinergic specific measures (e.g., BEERS criteria,
Drug Burden Index(total)) were used
• Specific anticholinergic medications or groups of medications
(e.g., bladder antispasmodics) were assessed and not total
anticholinergic exposure.Study Selection Process
Studies identified through database searches were entered
RefWorks (ProQuest LLC, Ann Arbor, MI, USA) for
bibliographic management to remove duplicates. Studies were
transferred to Covidence systematic review software ©2019
(Veritas Health Innovation Ltd., www.covidence.org) for
screening, whereafter 13,197 studies remained after duplicate
removal. Titles and abstracts of records were screened by two of
three independent reviewers (shared between CS, KY, MK) to
determine whether inclusion criteria were met. For a title to be
excluded, two independent reviewers had to agree on exclusion;
where disagreement occurred, a third independent reviewer
(TQ) would aid resolution. Thereafter, full texts of potentially
eligible studies (n=119) were obtained and further independentlyApril 2020 | Volume 11 | Article 570
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inclusion criteria to determine eligibility. Study authors were
contacted where full texts could not be sourced. Again, a third
independent reviewer (TQ) resolved any disagreements
regarding exclusion. Included studies had their citations
reviewed through PubMed and reference lists hand searched to
check for further eligible studies. Reference lists and citations of
recent seminal articles (Salahudeen et al., 2015) were
also searched.
Data Collection, Extraction, and Analysis
A data extraction template was developed in accordance with
guidance by the Cochrane Prognostic Review Group framework
(https://methods.cochrane.org/prognosis/our-publications)
requirements for data. Key data extracted included study
characteristics (e.g., publication date, country, study setting),
population descriptives, ACB measure(s) used, types of data
(e.g., continuous, ordinal), the timing of predictor, and
outcome variables, covariates adjusted for, statistical plan and
results. Data was extracted by two of three independent reviewers
(KG, CS, MT); any disagreements were resolved by a third
independent reviewer (RS). Thereafter, data were transferred to
a Microsoft Excel 2016 (https://products.office.com/en-gb/excel)
sheet and imported to Comprehensive Meta-Analysis (CMA)
(v3.3.070 Biostat, Englewood, USA; https://www.meta-analysis.
com/) for analysis, with forest plots produced where appropriate.
All meta-analysis data presented compared ACB = 0 with
ACB >0.
Risk of Bias Assessment—QUIPS
The quality and risk of bias of included studies was assessed by
the Quality in Prognosis Studies tool, developed by the Cochrane
Prognosis Methods Group (QUIPS, available: https://methods.
cochrane.org/sites/methods.cochrane.org.prognosis/files/public/
uploads/QUIPS%20tool.pdf). The QUIPS tool comprises of six
areas: study participation, attrition, prognostic measurement,
outcome measurement, study confounding, and statistical
analysis. The wording of the QUIPS anchoring statement was
modified to be suitable for the current review question as
recommended. Any published baseline measure of ACB was
acceptable and adjusting for a minimum set of confounders (age,
sex, and any measure of comorbidity burden) was considered
adequate for assessing quality of statistical analysis. Risk of bias
assessments were carried out by two of three reviewers (KG, CS,
MT). Any discrepancies were resolved by a third independent
reviewer (RS). The summary of the QUIPS risk of bias
assessment can be found in Figure 4.
Strategy for Data Synthesis
Data were analyzed and split into two primary groups: hazard
ratio and odds ratio data. Data were further stratified according
to the ACB measurement tool utilized and whether these data
were continuous or ordinal. Where possible, analyses were
further stratified by strength of ACB exposure into “high” or
“low,” though precise definitions varied by study and were
reported individually for each meta-analysis (see Table 3 for
definitions of “high” and “low” categories within each study).Frontiers in Pharmacology | www.frontiersin.org 3Meta-analyses were undertaken on comparable datasets. 95%
confidence intervals (CIs) were utilized. CMA was used to
facilitate the production of meta-analyses and forest plots.
Random effects models were used.
If multiple results were provided in the same study, the most
appropriate result was chosen to be included in the meta-
analyses by two researchers (CS and KG) so as not to duplicate
the same study population within one meta-analysis (see results).
For Lattanzio 2018 A (Lattanzio et al., 2018a) and Lattanzio 2018
B (Lattanzio et al., 2018b), one cohort was used for both studies.
Again, to avoid cohort duplication, data assessing ACB on the
cohort as a whole (Lattanzio 2018 A (Lattanzio et al., 2018a))
were chosen as more generalizable than data produced after
stratification of individuals by Basic Activities of Daily Living
(BADL) scores.
Where available, data adjusted for covariates (e.g., age, sex,
comorbidities) and/or temporal changes in ACB were given
priority over unadjusted, baseline ACB-only data. For studies
which had multiple follow-up periods, the follow up period most
comparable to the other studies within the review was chosen.
Where data were considered too heterogenous to be included in
any meta-analysis, they were analyzed narratively.
Quality Assessment—GRADE
The quality of the body of evidence collected throughout this
systematic review was assessed with the GRADE tool. The
GRADE tool assesses the quality of evidence for given
outcomes of studies, as opposed to assessing the evidence from
individual studies (Guyatt et al., 2008). Evidence quality was
assessed by two researchers (CS, KG) across seven criteria; study
limitations, inconsistency, indirectness, imprecision, publication
bias, effect size and dose-effect. Subsequently, studies were
upgraded or downgraded in relation to the seven criteria and a
final decision was made as to the quality of evidence (ranging
from high quality to very low quality). This process was adapted
for prognostic review studies in accordance with the
recommendations laid out by Huguet et al. (2013).RESULTS
Twenty papers, including 18 cohorts, were included. Reasons for
exclusion are presented in the Preferred Reporting Items for
Systematic Reviews and Meta-Analyses (PRISMA) flowchart
(Figure 1). The PRISMA checklist is outlined in Supplementary
Table 2. An electronic database search identified 19,224 studies;
these reduced to 13,197 after removing duplicates. Titles were
screened manually for eligibility whereafter 119 articles remained.
Full texts were assessed leaving 20 articles. Most common reasons
for exclusion were studies assessing the wrong outcome and using
non ACB-specific measures. Descriptive information on the
included papers can be found in Table 1.
A total of 498,056 older individuals participated across the 18
studies, with a sample size range of 71 (Mangoni et al., 2013) to
245,410 (McIsaac et al., 2018) people. Two identical study
cohorts were each used twice in separate papers (LattanzioApril 2020 | Volume 11 | Article 570
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Lowry 2011 (Lowry et al., 2011) and 2012 (Lowry et al., 2012)); as
a result, participants were only counted once. Ages ranged from
mean 71 years (SD 12) (Agar et al., 2010) to median 93 years
(IQR 91-95) (Kidd et al., 2014). Fifteen studies were based in
Europe, three in North America and two in Australia (see
Table 1).
Eight ACB measures were used (Han et al., 2001; Carnahan
et al., 2006; Hilmer et al., 2007; Boustani et al., 2008; Chew et al.,
2008; Rudolph et al., 2008; Durán et al., 2013; Klamer et al., 2017).
The most frequently used were the Anticholinergic Cognitive
Burden Scale (ACBS; n=9), Anticholinergic Risk Scale (ARS;
n=8), Anticholinergic Drug Scale (ADS; n=4) and the Drug
Burden Index(anticholinergic) (DBI(antichol); n=2). Measures
reported once each were the list of Chew (hereon referred to as
“Chew”), Clinician Rated Anticholinergic Scale (CrAS), Duran’s
list and the Muscarinic Acetylcholinergic Receptor ANTagonist
Exposure (MARANTE) scale. Summaries of each anticholinergic
measure can be found in Supplementary Table 3. Four papers
used more than one ACB measure in their analysis. Sevilla-
Sánchez et al. (2018) used two measures, however one of these
(DBI(total)) was not anticholinergic-specific (see exclusion criteria).
The data for this measure were therefore excluded from analysis.Frontiers in Pharmacology | www.frontiersin.org 4Forest plot of all hazard ratios and odds ratios of all-cause
mortality within the evidence base can be found in Figures 2 and
3, respectively. Meaningful meta-analysis of all studies was not
possible due to high heterogeneity in study design and reporting.
Risk of Bias Assessment
Results of the QUIPS risk of bias assessment are available in
Figure 4. Of the 20 papers in the final analysis, 15 were
considered high risk of bias in at least one or more QUIPS
category. Of these, three papers (Vetrano et al., 2016; Wauters et
al., 2017; Aalto et al., 2018) had high risk of bias scores in four or
more of the six QUIPS categories. A common area of bias
included a lack of reporting of prognostic factor measurement
—no study had assessed anticholinergic intake by two
independent means. Additionally, studies presented with a lack
of justification for the adjustment of certain confounders, as well
as overall lack of adjustment or possible over-adjustment for
confounders. Only two studies adjusted for temporal change in a
patient’s ACB exposure. Furthermore, statistical reporting was
frequently not detailed and access to study protocols was limited.
Frequently, unadjusted results were not reported as opposed to
adjusted results, negating the possibility of unadjusted meta-
analysis synthesis.FIGURE 1 | Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flowchart depicting the study screening and selection process.April 2020 | Volume 11 | Article 570
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Study Cohort
size (N)
Design Setting Country F/up (months) Sex (Female) Age (Mean (SD),
unless other-
wise specified)
ACBS
Chatterjee et al. (2017) 224,740 Nested case
control
Current and former nursing home
residents
USA 60 and 90 days
prior to death
Cases: 34,819
(77.47%)
Cases: 83.47
(7.64
Controls: 139,276
(77.47%)
Controls: 83.43
(7.61)
Cross et al. (2017) 964 Retrospective
cohort
Patients attending memory clinics Australia 36 months and 90
days
456 (47.3%) 77.6 (7.4)
Egberts et al. (2017) 905 Retrospective
cohort
Geriatric ward admissions Netherlands In-hospital mortality
(LOS median 8
days, IQR 5-11)
468 (51.7%) 81.0 (7.03)
Fox et al. (2011) 12,423 Prospective
cohort
Community-dwelling and
institutionalised older persons
England,
Wales
24 7,454 (60%) 75 (6.8)
Kidd et al. (2014) 419 Prospective
cohort
Acute medical assessment units or
acute geriatric ward
England,
Scotland
In-hospital mortality
– 3 day, 7 day and
overall
68% Median 92.9 (IQR
94.1-95.1)
Lattanzio et al. (2018a) 807 Prospective
cohort
Patients discharged from acute
geriatric care wards
Italy 12 438 (54.3%) 81 (7.4)
Lattanzio et al. (2018b) 807 Prospective
cohort
Patients discharged from acute
geriatric care wards
Italy 12 438 (54.3%) 81 (7.4)
Mangoni et al. (2013) 71 Prospective
cohort
Patients admitted with hip
fractures and scheduled for
surgery
Netherlands 3 and 12 70.40% 84 (6)
Vetrano et al. (2016) 3,761 Retrospective
cohort
Nursing homes Italy 60 72% 83 (7)
ADS
Chatterjee et al. (2017) 224,740 Nested case
control
Current and former nursing home
residents
USA 60 and 90 days
prior to death
Cases: 34,819
(77.47%)
Cases: 83.47
(7.64)
Controls: 139,276
(77.47%)
Controls: 83.43
(7.61)
Mangoni et al. (2013) 71 Prospective
cohort
Patients admitted with hip
fractures and scheduled for
surgery
Netherlands 3 and 12 70.40% 84 (6)
Sarbacker et al. (2017) Prospective
cohort
Hispanic Established Populations
for the Epidemiologic Study of the
Elderly
USA 108 63.3% 74.56 (95%CI
74.26–74.87)
Sevilla-Sánchez et al.
(2018)
Prospective
cohort
Acute care geriatric unit Spain 12 65.50% 86.8 (5.37)
ARS
Aalto et al. (2018) 2432 Prospective
cohort
Nursing homes and assisted living
facilities
Finland 12 0 DAPs: 886 (74%) 0 DAPs: 85 (7)
1 DAP: 516 (76%) 1 DAP: 84 (8)
2 DAPs: 237 (76%) 2 DAPs: 82 (8)
3+ DAPs: 183
(74%)
3 DAPs: 81 (7)
Egberts et al. (2017) 905 Retrospective
cohort
Geriatric ward admissions Netherlands In-hospital mortality
(LOS median 8
days, IQR 5-11)
468 (51.7%) 81 (7.03)
Gutiérrez-Valencia et al.
(2017)
921 Prospective
cohort
Patient discharged from geriatric
and acute care wards
Italy 12 509 (55.3%) 81.2 (7.4)
Kumpula et al. (2011) 1004 Prospective
cohort
Long term care wards (facilities
which provide more intensive care
than regular nursing homes)
Finland 12 75% 81.3 (10.9)
Landi et al. (2014) 1490 Prospective
cohort
Nursing homes Italy 12 71.50% ARS 0: 85 (8)
ARS ≥1: 82 (8)
Lowry et al. (2011) 362 Prospective
cohort
Acute geriatric unit Scotland In-hospital mortality
(LOS median 11
days, IQR 4-24)
59.40% 84 (7)
(Continued)Frontiers in Pharmacology | www.frontiersin.org 5 April 2020 | Volume 11 | Article 570
Graves-Morris et al. Prognosticating Death Using Anticholinergic BurdenTABLE 1 | Continued
Study Cohort
size (N)
Design Setting Country F/up (months) Sex (Female) Age (Mean (SD),
unless other-
wise specified)
Mangoni et al. (2013) 71 Prospective
cohort
Patients admitted with hip
fractures and scheduled for
surgery
Netherlands 3 and 12 70.40% 84 (6)
McIsaac et al. (2018) 245,410 Retrospective
cohort
Noninstitutionalised patients
admitted for an elective, major
non-cardiac surgery
Canada 90 days ARS 0: 49.9% ARS 0: 74 (6)
ARS 1-2: 61.0% ARS 1-2: 74 (6)
ARS≥3: 60.2% ARS ≥3: 75 (6)
DBI (anticholinergic)
Lowry et al. (2012) 362 Prospective
cohort
Acute geriatric unit Scotland In-hospital mortality
(LOS median 11
days, IQR 4-24)
59.40% 84 (7)
Mangoni et al. (2013) 71 Prospective
cohort
Patients admitted with hip
fractures and scheduled for
surgery
Netherlands 3 and 12 70.40% 84 (6)
Miscellaneous scales
Agar et al. (2010) (Clinician
Rated Anti-Cholinergic
Scale (modified version)
(CrAS))
112 Prospective
cohort
Southern Adelaide Palliative Care
Services - Inpatients and
outpatients
Australia Until death (8.9
weeks (SD 11.6))
58 (52%) 72 (12)
Egberts et al. (2017)
(Chew)
905 Prospective
cohort
Geriatric ward admissions Netherlands In-hospital mortality
(LOS median 8
days, IQR 5-11)
468 (51.7%) 81 (7.03)
Gutiérrez-Valencia et al.
(2017)
(Duran’s list)
921 Prospective
cohort
Patients discharged from acute
and geriatric care wards
Italy 12 509 (55.3%) 81.2 (7.4)
Wauters et al. (2017)
(MARANTE scale)
503 Prospective
cohort
General Practitioner centres Belgium 18 61% 84.4 (range 80–
102)Frontiers in Pharmacology | www.frontiersin.org 6 April 2020 | VolumACBS, Anticholinergic Cognitive Burden Scale; ADS, Anticholinergic Drug Scale; ARS, Anticholinergic Risk Scale; DAP(s), Drug(s) with anticholinergic properties; DBI (anticholinergic),
Anticholinergic Component of the Drug Burden Index; LOS = l, Length of Stay; IQR, Interquartile Range.FIGURE 2 | Forest plot of all hazard ratios of all-cause mortality within the evidence base. A summary statistic is not included as the same study population is used
more than once. ACBS, Anticholinergic Cognitive Burden Scale; ADS, Anticholinergic Drug Scale; ARS, Anticholinergic Risk Scale; DBI, Anticholinergic Component of
the Drug Burden Index. Variation was apparent in how individual studies classed “high” and “low” exposure through ACB measures. Lattanzio 2018 A and Vetrano
2016 classed “low” exposure as a score of ACBS one and “high” exposure as ACBS two or more. Kumpula 2011 and McIsaac 2018 classed “low” exposure as
ARS one to two and “high” exposure as ARS three or more.e 11 | Article 570
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Full GRADE results can be viewed in Table 2. Overall, the quality
of the evidence base was considered very low for each ACB
measure. Issues arose across the GRADE criteria and included:
studies having a high risk of bias, limited generalizability of study
setting, small effect sizes, risk of publication bias, and
heterogenous reporting of potential dose-effect. For publication
bias assessment, it was not possible to build funnel plots due to
insufficient studies and variation in statistical effect sizes.
Anticholinergic Cognitive Burden Scale
(ACBS)
Full information regarding study results can be found in Table 3.
Nine studies Chatterjee et al. (2017), Cross et al. (2017), Egberts
et al. (2017), Fox et al. (2011), Kidd et al. (2014), Lattanzio et al.,
(2018a), Lattanzio et al. (2018b), Mangoni et al. (2013) and
Vetrano et al. (2016) involving 244,090 individuals were
included, with cohort sizes ranging from 71 Mangoni et al.
(2013) to 224,740 Chatterjee et al. (2017). Two studies
Lattanzio et al. (2018a); Lattanzio et al. (2018b) utilized the
same study population; subsequently, their population was only
counted once within the total. Five took place in hospital settings,
two in nursing homes, one incorporated community and nursing
home residents and one in an outpatient clinic setting.
Summary statistics for “low” anticholinergic exposure
measured with the ACBS were HR 1.39 (95%CI 1.1–1.75) and
OR 1.53 (95%CI 1.34–1.75); for “high” ACBS these were HR 1.47
(95%CI 1.19–1.81) and OR 1.37 (95% 1.12–1.68) Figure 5.
Continuous data was analyzed separately, yielding a summary
HR of 1.87 (95%CI 1.07–1.32), however it should be noted that
within this, results from Mangoni et al. (2013) were unadjusted.
Data for Lattanzio et al. (2018b) was not included in meta-
analysis so as not to include the same cohort twice. However, the
results from this study were stratified into individuals with a
dependency in one or more Basic Activities of Daily Living
(BADL) and those without. These results indicated that those
who were dependent in at least one BADLwere more likely to have
a significant association between greater ACB and mortality (HR
1.28 (95%CI 1.11–1.49)) than those who did not (HR 0.98 (95%CI
0.75–1.28). Results from Mangoni et al. (2013) were unadjusted.
Anticholinergic Drug Scale (ADS)
The ADS was reported in four papers Chatterjee et al. (2017),
Mangoni et al. (2013), Sarbacker et al. (2017), and Sevilla-Sánchez
et al. (2018). The total population size was 226,543 individuals,
with sample sizes ranging from 71 Mangoni et al. (2013) to
224,740 Chatterjee et al. (2017). Two studies took place in hospital
settings, one in nursing homes and one was community-based.
Meta-analysis of three studies Mangoni et al. (2013),
Sarbacker 2017 (Sarbacker et al., 2017), Sevilla-Sánchez et al.
(2018) produced a summary HR of 1.1 (95%CI 1.04–1.15). Data
not included in the meta-analysis Chatterjee et al. (2017),
comparing “high” ADS (ADS 2/3) to no ADS 90 days before
death indicated a stronger association [OR 1.37 (95%CI 1.34–
1.4) (Figure 2)]. Data for low or continuous ACB within the
Chatterjee et al. (2017) cohort were not reported. Results from
Mangoni et al. (2013) were unadjusted.Frontiers in Pharmacology | www.frontiersin.org 7T
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Graves-Morris et al. Prognosticating Death Using Anticholinergic BurdenTABLE 3 | Summary of results of papers included in review (n=20), stratified by anticholinergic burden (ACB) measure.
Study Cohort
size (N)
Design Setting F/up (months) Unadjusted Results – HR/
OR (95%CI)
Adjusted Results – HR/OR (95%CI)
ACBS
Chatterjee et al.
(2017)
224,740 Nested case
control
Current and former
nursing home
residents
60 and 90 days prior
to death
NR ACBS level 2/3, prescribed within 90 days:
OR 1.24 (1.21, 1.27)a
Cross et al.
(2017)
964 Retrospective
cohort
Patients attending
memory clinics
36 months and 90
days
Baseline ACBS score HR
1.27 (1.15-1.40)
Baseline ACBS score:
HR 1.15 (1.01-1.31)b
ACBS score over study
period HR 1.29 (1.19-1.39)
ACBS score over study period:
HR 1.18 (1.06-1.32)b
Egberts et al.
(2017)
905 Retrospective
cohort
Geriatric ward
admissions
Up to discharge
(median 8 days, IQR
5-11)
NR Low (1-2): OR 1.52 (0.79–2.93)c
High (≥3): OR 1.47 (0.66–3.25)c
Fox et al. (2011) 12,423 Prospective
cohort
Community-dwelling
and institutionalised
older persons
24 NR Continuous: OR 1.26 (1.20–1.32)d
Low (≥1): OR 1.56 (1.36–1.79)d
High (≥2): OR 1.68 (1.30–2.16)d
Kidd et al.
(2014)
419 Prospective
cohort
Acute medical
assessment units or
acute geriatric ward
In-hospital mortality –
3 day, 7 day and
overall
Overall mortality:
1: OR 1.04 (0.58–1.86)
Overall mortality:
Low (1): OR 1.01 (0.53–1.95)f
≥2: OR 1.10 (0.60–2.04) High (≥2): OR 1.23 (0.58–2.63)f
Lattanzio et al.
(2018a)
807 Prospective
cohort
Patients discharged
from acute geriatric
care wards
12 NR Low (1): HR 1.19 (0.75–1.90)i
High (≥2): HR 1.69 (1.09–2.65)i
Adjusted for ACBS at 3-month follow-up:
HR 1.33 (0.97–2.05)i
Lattanzio et al.
(2018b)
807 Prospective
cohort
Patients discharged
from acute geriatric
care wards
12 NR No BADL dependency (n = 537)
Low (1): HR 0.92 (0.45–1.89)j
High (≥2): HR 1.06 (0.50–2.34)j
Continuous: HR 0.98 (0.75–1.28)j
Dependency in ≥ 1 BADL (n= 270)
Low (1): HR 1.50 (0.81-2.73)j
High (≥2): HR 2.25 (1.22–4.14)j
Continuous: HR 1.28 (1.11–1.49)j
Adjusted for ACBS at 3-month follow-up
(with BADL dependency)
High (≥2): HR 2.18 (1.20–3.98)j
Mangoni et al.
(2013)
71 Prospective
cohort
Patients admitted with
hip fractures and
scheduled for surgery
3 and 12 Univariate analysis of 3-
month mortality
Continuous: HR 1.1 (0.7–
1.8)
NR
Univariate analysis of 1-year
mortality
Continuous: HR 1.1 (0.7–
1.8)
NR
Mangoni et al.
(2013)
3,761 Retrospective
cohort
Nursing homes 60 NR Low (1): HR 1.46 (1.12–1.9)p
High (≥2): HR 1.41 (1.11–1.79)p
ADS
Chatterjee et al.
(2017)
224,740 Nested case
control
Current and former
nursing home
residents
60 and 90 days prior
to death
ADS level 2/3 (high), prescribed within 90
days:
OR 1.37(1.34, 1.40)a
Mangoni et al.
(2013)
71 Prospective
cohort
Patients admitted with
hip fractures and
scheduled for surgery
3 and 12 Univariate analysis of 3-
month mortality
HR 1.3 (0.9–1.9)
NR
Univariate analysis of 1-year
mortality
HR 1.2 (0.9–1.6)
Sarbacker et al.
(2017)
1,497 Prospective
cohort
Hispanic Established
Populations for the
108 (9 years) HR 1.12 (1.07–1.17) Continuous: HR 1.09 (1.04–1.15)n
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Graves-Morris et al. Prognosticating Death Using Anticholinergic BurdenTABLE 3 | Continued
Study Cohort
size (N)
Design Setting F/up (months) Unadjusted Results – HR/
OR (95%CI)
Adjusted Results – HR/OR (95%CI)
Epidemiologic Study of
the Elderly
Sevilla-Sánchez
et al. (2018)
235 Prospective
cohort
Acute care geriatric
unit
12 NR Continuous: HR 1.54 (0.74–3.18)o
High (> 3) vs low (< 3) use:
HR 1.05 (0.75–1.47)o
ARS
Aalto et al.
(2018)
2,432 Prospective
cohort
Nursing homes and
assissted living facilties
12 No. of deaths during 1 year
follow up (%)
p value: 0.11
NR
0 DAPs: 238 (20%)
1 DAP: 134 (20%)
2 DAPs: 56 (18%)
3+ DAPs: 50 (20%)
Egberts et al.
(2017)
905 Retrospective
cohort
Geriatric ward
admissions
Up to discharge
(median 8 days, 5–11
IQR)
NR Low (1-2): OR 1.2 (0.63–2.27)c
High (≥3): OR 1.22 (0.47–3.13)c
Gutiérrez-
Valencia et al.
(2017)
921 Prospective
cohort
Patient discharged
from geriatric and
acute care wards
12 1: 1.68 (1.10, 2.57) Low (1): 0.96 (0.51, 1.81)e
≥2: 0.87 (0.4, 1.91) High (≥2): 0.44 (0.12, 1.59)e
Kumpula et al.
(2011)
1,004 Prospective
cohort
Long term care wards 12 NR Low (1-2): HR 1.08 (0.84–1.41)g
High (≥3): HR 1.05 (0.75–1.46)g
Landi et al.
(2014)
1,490 Prospective
cohort
Nursing homes 6 and 12 Continuous: OR 1.02 (0.95–1.17)h
Lowry et al.
(2011)
362 Prospective
cohort
Acute geriatric unit In-hospital mortality
(LOS median 11 days,
IQR 4-24)
Continuous: HR 1.31
(0.97–1.77)
Continuous: 1.04 (0.67–1.62)k
ARS (dose-
adjusted) continuous:
1.43 (0.97-2.12)
ARS (dose-
adjusted) continuous:
1.12 (0.64–1.96)k
Mangoni et al.
(2013)
71 Prospective
cohort
Patients admitted with
hip fractures and
scheduled for surgery
3 and 12 Univariate analysis of 3-
month mortality
Continuous: HR 1.6 (1.2–
2.2)
Multivariate 3-month mortality
Continuous: HR 2.2 (1.2-3.7)l
Univariate analysis of 1-year
mortality
Continuous: HR 1.4 (1.1–
1.8)
McIsaac et al.
(2018)
245,410 Retrospective
cohort
Noninstitutionalised
patients admitted for
an elective, major non-
cardiac surgery
90 days 1-2: HR 1.49 (1.40–1.59) Low (1-2): HR 1.15 (1.08–1.22)m
≥3: HR 1.39 (1.30–1.49) High (≥3): HR 1.14 (1.06–1.23)m
DBI (anticholinergic)
Lowry et al.
(2012)
362 Prospective
cohort
Acute geriatric unit In-hospital mortality
(LOS median 11 days,
IQR 4-24)
Continuous: HR 1.09
(0.46–2.57)
Continuous: HR 1.10 (0.44–2.74)k
Mangoni et al.
(2013)
71 Prospective
cohort
Patients admitted with
hip fractures and
scheduled for surgery
3 and 12 Univariate analysis of 3-
month mortality
Continuous: HR 4.5 (1.2–
16.7)
NR
Univariate analysis of 1-year
mortality
Continuous: HR 3.2 (1.1–
9.4)
Miscellaneous scales
Agar et al.
(2010)
112 Prospective
cohort
Southern Adelaide
Palliative Care Services
Until death (mean
survival time: 8.9
“Log-rank data showed no
evidence that survival
(Continued)Frontiers in Pharmacology | www.frontiersin.org 9 April 2020 | Volume 11 | Article 570
Graves-Morris et al. Prognosticating Death Using Anticholinergic BurdenAnticholinergic Risk Scale (ARS)
Eight papers reported use of the ARS Aalto et al. (2018), Egberts
et al. (2017), Gutiérrez-Valencia et al. (2017), Kumpula et al.
(2011), Landi et al. (2014), Lowry et al. (2011), Mangoni et al.
(2013), McIsaac et al. (2018). Cohort sizes ranged from 71
Mangoni et al. (2013) to 245,410 McIsaac et al. (2018) and
included 252,595 participants. Six cohorts were based in hospital
settings and two were in nursing home settings.
Meta-analysis of categorical data for “low” ARS produced
summary HR 1.15 (95%CI 1.08–1.22) and OR 1.07 (95%CI 0.68–
1.68) and “high” ARS produced HR 1.14 (95%CI 1.06–1.22) and
OR 0.81 (95%CI 0.3–2.16). A further two studies Lowry et al.
(2011), Mangoni et al. (2013) comprised a meta-analysis of
continuous ARS data and resulted in a summary HR of 1.48
(95%CI 0.71–3.08).
Two papers were not included in the meta-analysis Aalto et al.
(2018), Landi et al. (2014). It should be noted that the cumulative
nature of the ARS measure was not applied in the analysis of
Aalto et al. (2018); rather, the medications listed within the ARSFrontiers in Pharmacology | www.frontiersin.org 10were used to sum the number of anticholinergic medications a
patient was taking. Landi et al. (2014) reported OR 1.02 (95%CI
1.02–0.92–1.12).
Drug Burden Index—Anticholinergic
Component (DBI(antichol))
Two prospective cohort studies reported use of the DBI(antichol)
[Lowry 2012 (Agar et al., 2010), Mangoni et al. (2013) and
included a total population of 433 older patients in acute care
settings. Lowry 2012 (Agar et al., 2010) reported HR 1.10 (95%CI
0.44–2.74) and Mangoni et al. (2013) reported HR 3.2 (1.1–9.4).
Results from Mangoni et al. (2013) [HR 3.2 (95%CI 1.1–9.35)]
were unadjusted.Other ACB Measures
Four papers (three prospective cohorts, one retrospective cohort)
reported measures used only once each Agar et al. (2010),
Egberts et al. (2017), Gutiérrez-Valencia et al. (2017),TABLE 3 | Continued
Study Cohort
size (N)
Design Setting F/up (months) Unadjusted Results – HR/
OR (95%CI)
Adjusted Results – HR/OR (95%CI)
[Clinician Rated
Anti-Cholinergic
Scale (modified
version)]
- Inpatients and
outpatients
weeks (SD 11.6,
median 5.3, IQR 0.2-
84.4)
differed significantly
between the three groups”
Egberts et al.
(2017)
(Chew)
905 Prospective
cohort
Geriatric ward
admissions
Until hospital
discharge (LOS
median 8 days, IQR 5-
11)
NR Low (0.5–1): OR 1.01 (0.56–1.83)c
High (≥1.5): OR 1.39 (0.66–2.92)c
Gutiérrez-
Valencia et al.
(2017)
(Duran’s list)
921 Prospective
cohort
Patients discharged
from acute and
geriatric care wards
12 1: OR 1.84 (1.27, 2.65) Low (1): OR 1.69 (1.02, 2.82)e
≥2: OR 1.52 (0.86, 2.68) High (≥2): OR 1.52 (0.86, 2.68)e
Wauters et al.
(2017)
(MARANTE
scale)
503 Prospective
cohort
General Practitioner
centres
18 Continuous: HR 1.22
(1.02–1.47)
Continuous: HR 1.09 (0.87–1.36)q
Low (0.5–1.5): HR 1.52
(0.68–3.39)
Low (0.5–1.5): HR 1.31 (0.57–3.02)q
High (≥2): HR 2.77 (1.43–
5.38)
High (≥2): HR 2.20 (1.03–4.67)qPapers appear multiple times throughout this table if they have reported their results using more than one ACBmeasure. “Continuous” denotes when an ACBmeasure has been used as a
continuous variable during analysis. ACBS, Anticholinergic Cognitive Burden Scale; ADS, Anticholinergic Drug Scale; ARS, Anticholinergic Risk Scale; BADL, Basic Activities of Daily Living;
DAP(s), Drug(s) with anticholinergic properties; DBI (anticholinergic), anticholinergic component of the Drug Burden Index; HR, Hazard Ratio; IQR, Interquartile Range; LOS, Length of Stay;
NR, Not reported; OR, Odds Ratio. Adjustments: aAdjusted for demographic characteristics such as race; co-morbidities such as myocardial infarction, heart failure, vascular diseases,
dementia, cerebrovascular events, rheumatological diseases, mild liver disease, pulmonary disorders, renal diseases, ulcer, hemiplegia, diabetes, cancer, metastasis, moderate/chronic
liver disease; and duration of depression. bBaseline age, gender, education, dementia/MCI diagnosis, total number of medications, MDBI score, MMSE, SMAF, and NPI score. cAge, sex,
Charlson Comorbidity Index (CCI), number of nonanticholinergic drugs and delirium at any time during the hospital stay. dAge, sex, baseline MMSE score, education, social class, number
of nonanticholinergic medications, and number of health conditions. eAge, sex, number of chronic diseases, MMSE, impaired ADL and number of non-anticholinergic medications. fAge,
no of pre-morbid conditions, ischemic heart disease, no of medications, creatinine and urea. gAdjusted for age, sex, mini nutritional assessment. hAge, gender, comorbidities, baseline
functional impairment and cognitive impairment. iAge, sex, cognitive impairment, depression, number of lost BADL, hypertension, heart failure, diabetes, coronary artery disease, atrial
fibrillation, peripheral arterial disease, stroke, chronic obstructive pulmonary disease, cancer and number of medications. jAge, sex, cognitive impairment, history of falls, depression,
number of medications and hypertension, heart failure, diabetes, coronary artery disease, atrial fibrillation, peripheral arterial disease, stroke, chronic obstructive pulmonary disease, and
cancer. kAdjusted for age, sex, institution, dementia, CCI, number of nonanticholinergic drugs, hospital site, Barthel Index category (under 50 vs. 50+). lAge, sex, CCI and preadmission
cognitive impairment. mAge, sex, income quartile, comorbidities, one-year mortality risk, total hip replacement (please see paper for extensive list of covariates). nAge, sex, any self-reported
diabetes, stroke, smoking, hypertension and cancer. oAge, sex, provenance, age-adjusted CCI, cognitive impairment and geriatric syndromes. pAge, sex, activities of daily living,
Depression Rating Scale, Cognitive Performance Scale, dementia, heart failure, stroke, chronic obstructive pulmonary disease, cancer, diabetes, IHD, and hip fracture. qNumber of
medications & level of multi-morbidity (0–9).April 2020 | Volume 11 | Article 570
Graves-Morris et al. Prognosticating Death Using Anticholinergic BurdenFIGURE 3 | Forest plot of all odds ratios of all-cause mortality within the evidence base. A summary statistic is not included as the same study population is used
more than once. ACBS, Anticholinergic Cognitive Burden Scale; ADS, Anticholinergic Drug Scale; ARS, Anticholinergic Risk Scale. Variation was apparent in how
individual studies classed “high” and “low” exposure through ACB measures. “Low” anticholinergic exposure data for Chatterjee 2017 was not given. “High”
exposure for Chatterjee 2017 ACBS/ADS was classed as a score of 2 or 3. Egberts 2017 classed “low” exposure as ACBS/ARS one to two and “high” exposure as
ACBS/ARS three or more. Kidd 2014 classed “low” exposure as ACBS one and “high” exposure as ACBS two or more. Fox 2011 classed “low” exposure as ACBS
one or more and “high” as ACBS two or more. Gutierrez-Valencia 2017 classed “low” exposure as ARS one and “high” as ARS two or more.FIGURE 4 | Summarized results of the Quality in Prognosis Studies (QUIPS) risk of bias assessment.FIGURE 5 | Forest plot of odds ratios of all-cause mortality grouped by anticholinergic exposure level using the ACBS (Anticholinergic Cognitive Burden Scale).
“Low” anticholinergic exposure data for Chatterjee 2017 was not given. “High” exposure for Chatterjee 2017 ACBS was classed as a score of 2 or 3. Egberts 2017
classed “low” exposure as ACBS one to two and “high” exposure as ACBS three or more. Kidd 2014 classed “low” exposure as ACBS one and “high” exposure as
ACBS two or more. Fox 2011 classed “low” exposure as ACBS one or more and “high” as ACBS two or more.Frontiers in Pharmacology | www.frontiersin.org April 2020 | Volume 11 | Article 57011
Graves-Morris et al. Prognosticating Death Using Anticholinergic BurdenWauters et al. (2017). These measures were: Clinician Rated
Anticholinergic Scale (CrAS); Chew; Duran’s list; MARANTE.
Agar et al. (2010) stated “Log-rank data showed no evidence
that survival differed significantly between the three groups,”
however, no quantitative data were provided. Significant
associations between ACB and mortality were produced by
Gutiérrez-Valencia et al. (2017) [Duran’s=1, OR 1.69 (95%CI
1.02–2.82) and Wauters et al. (2017) (MARANTE “high” ≥2: HR
2.20 (95%CI 1.03–4.67)].
A Comparison of ACB Measures
Four papers utilized more than one measure to assess ACB
within the same cohort of individuals Chatterjee et al. (2017),
Egberts et al. (2017), Gutiérrez-Valencia et al. (2017), Mangoni
et al. (2013). Chatterjee et al. (2017) compared ADS with ACBS,
whereby ADS resulted in significantly higher odds ratios than
ACBS [ADS level 2/3: OR 1.37 (95%CI 1.34, 1.40); ACBS level 2/
3: OR 1.24 (95%CI 1.21, 1.27)]. No data were given for low
anticholinergic exposure for either scale.
Data provided by Egberts et al. (2017) compared ARS, ACBS,
and Chew. Most results showed no significant association, with
wide CIs (Table 3). ACBS exhibited higher odds ratios compared
to ARS and Chew, but the differences were not statistically
significant. Gutiérrez-Valencia et al. (2017) compared ARS and
Duran’s list. There was a positive association between ACB
measured by Duran’s list and mortality (OR 1.69 (95%CI 1.02–
2.82), while the association between ARS and mortality was not
significant. Mangoni et al. (2013) compared ACBS, ADS, ARS,
and DBI(antichol), however, interpretation of these results were
limited as analyses for all measures (apart from ARS three-
month mortality) were not adjusted for confounders. Hazard
ratios were small and not statistically significant for ACBS
and ADS and increased with ARS (HR 2.2 (95%CI 1.2–3.7)
and DBI(antichol) (HR 3.2 (95%CI 1.1–9.4)).DISCUSSION
This is the first systematic review and meta-analysis assessing the
prognostic utility of individual ACB measures to predict
mortality specifically in individuals ≥65 years. Of 20 included
studies, 11 reported a significant association between ACB and
mortality and meta-analysis showed a positive association
between greater ACB and mortality. However, a dose-effect
response was not consistently apparent. The most frequently
used ACB measures were ACBS, ARS and ADS. Inter-study
variation and methodological heterogeneity between studies
precluded combined meta-analyses across all scales.
Our finding that greater ACB appears associated with increased
risk of mortality conflicts with the findings reported in the Fox et al.
(2014) systematic review, where no significant association between
ACB and mortality was identified. This may be because our review
focused on older people, where risk of mortality is much higher.
Also, the current review focused on use of any published ACB scale
whilst their review relied on defining ACB where medications were
included in the ACBS, a scale developed to predict cognitive declineFrontiers in Pharmacology | www.frontiersin.org 12rather than mortality. Another explanation may be that the
majority (n=14) of our included studies were published post-
2014, in line with increasing interest in this topic area, providing
a larger pool of data to analyze. Specifically, this allowed the
production of summary statistics, which were not possible in the
Fox et al. (2014) review.
It was not possible for us to declare one scale as superior to
another. Larger odds and hazard ratios were seen with the ACBS,
supporting the findings of Ruxton et al. (2015) where the ACBS
showed the largest effect sizes. The discrepancies in effect sizes
between scales may be a result of the variations in how differing
ACB measures assess the potency of an anticholinergic agent, as
highlighted by Salahudeen et al. (2015). For example, the ACBS
was developed through systematic review and a multi-disciplinary
panel to identify anticholinergic medications and assess their
potency (Boustani et al., 2008). On the other hand, the ARS was
developed by geriatricians and pharmacists within the Veterans
Affairs Boston Healthcare System via a literature review of the
most commonly prescribed medications among predominantly
male, veteran patients (Rudolph et al., 2008). The varying number
of drugs with anticholinergic properties included in eachmeasure,
along with their graded potencies, may contribute towards
variations in risk seen in the current review. The fact the three
most frequently used measures (ACBS, ARS, ADS) were all
developed in the USA may limit applications internationally
due to differing drug formularies between countries.
While our meta-analysis adds helpful new information to the
existing literature base, there are limitations that should be noted.
Firstly, the reporting of results between studies varied greatly; this
led to multiple levels of stratification before data could be grouped
for meta-analysis. Consequently, a large combined meta-analysis,
including all 20 studies, could not be created and meaningfully
interpreted. Once stratified by ACB measure, data were limited,
with some single meta-analyses containing only two studies.
Additionally, many studies did not have long enough follow-up
times. Also, the DBI(antichol) is the only ACB measure which takes
into account the dose of drug being administered to a patient, yet it
was only used twice in the current review, limiting the ability to
interpret whether having a scale which takes dose into account is
of benefit in assessing morality risk. Finally, the indication of
anticholinergic medications in each study is not known. It is
possible this may have an impact on mortality risk; while those
being treated for multiple conditions are more likely to be users of
anticholinergic medications, multi-morbidity alone is associated
with mortality risk (Wauters et al., 2017).
A clear advantage of the current study was the use of
contemporary best practice guidance for prognostic reviews;
the framework by the Cochrane Prognostic Review Group was
used in order to ensure the methodology and reporting within
this review adhered to high quality standards.
Another advantage of the current study was the analysis of
dose-effect within ACB measures (where possible), something not
apparent within other systematic reviews. In theory, a clear
increase in odds should have been visible in “high” exposure
groups compared to “low” throughout scales. Not only was this
not visible in odds data for ACBS and ARS when grouped by
exposure level, but the inverse was apparent on these twoApril 2020 | Volume 11 | Article 570
Graves-Morris et al. Prognosticating Death Using Anticholinergic Burdenoccasions. A contributing factor may have been the tendency for
participant numbers to be far lower in “high” exposure categories,
yet other clear mechanisms for this have not yet been established.
Further advantages were that this study assessed the risk of bias
using an appropriate prognostic review risk of bias tool, QUIPS,
and the body of evidence was assessed using the GRADE tool
(adapted specifically for prognostic studies). This provided a clear
understanding of the quality of the current evidence and where
improvements in future research can be made. Specifically, there is
a need for large-scale cohort studies supported by adequate sample
size calculations based on clinically meaningful effect sizes. The use
of multiple ACB measures on the same population reduces risk
from heterogeneity and would increase confidence in making
comparisons across the various ACB measures. Next, if a follow-
up period of over one year is used, then repeated ACB
measurements would prove useful to control for temporal
changes in patients’ anticholinergic exposure. Most studies
within the review did not adjust for temporal changes in ACB,
yet it is evident that patients’ prescriptions, and therefore ACB, will
change over time (Lu et al., 2015), which may have influenced risk.
Our findings provide further evidence of the risks associated
with the use of anticholinergic medications. This will help with
clinical decision making. Being aware of, and able to discuss
available evidence with patients will allow clinicians to make
more informed treatment decisions. From a provider
perspective, the economic implications of the use of
anticholinergic medications are not known and warrant further
investigation. At present we do not know how reducing or
stopping anticholinergic medications, and/or switching to non-
anticholinergic alternatives, may impact upon the costs of patient
care. We recommend those designing future trials aiming to de-
prescribe anticholinergic medications build economic evaluation
into their design.CONCLUSION
This systematic review identified twenty studies assessing ACB
and mortality using anticholinergic-specific measures in older
adults. Meta-analysis indicated an association between
anticholinergic exposure and higher risk of mortality using the
ACBS, ARS, and ADS. The evidence base was of poor quality
overall, with moderate to high risk of bias such that it was not
possible to ascertain if any ACB measure was superior toFrontiers in Pharmacology | www.frontiersin.org 13another, though the ACBS generally exhibited larger effect sizes
than other ACB measures. Future large-scale high-quality
research investigating validated measures is recommended.
Meanwhile, this review’s findings further add to the evidence
base that clinicians should be cautious around prescribing
anticholinergic medications to older persons.DATA AVAILABILITY STATEMENT
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